The metabolites of N- [(tdmethylamineboryl 
proposed metabolites afforded better activity than the parent compound against the growth of suspended and solid tumor cell lines. Evaluation of in vivo hypolipidemic activity demonstrated that the proposed metabolites of 1 were only moderately active and were generally less effective than the parent compound. Interestingly, L-phenylalanine methyl ester hydrochloride 3, which contains no boron atom, demonstrated equivalent hypolipidemic activity as the parent at 8 mg/kg/day in CF male mice. As anti-inflammatory agents the proposed metabolites demonstrated variable capacities to reduce foot pad inflammation. These compounds were similarly effective as the parent 1 at blocking local pain and were generally better than the parent at protecting CF male mice from LPS induced sepsis.
Introduction" N-[(Trimethylamineboryl)-carbonyl]-L-phenylalanine methyl ester 1 has been shown to possess antitumor, hypolipidemic, and antiinflammatory activities in vivo [1] . Disposition and distribution studies of this compound in CF male mice after intraperitoneal or intravenous administration indicated it was rapidly metabolized to N-[(trimethylamineboryl)-carbonyl]-Lphenylalanine in the plasma. In simulated gastric fluid, compound 1 was rapidly hydrolyzed to Lphenylalanine methyl ester 3 [2] . In order to address concerns that metabolites may be responsible for the pharmacological activity, synthesis and pharmacological evaluation of possible metabolic products of compound 1 were undertaken. The metabolic products evaluated included sodium N-[(trimethylamineboryl)-carbonyl]-L-phenylalanine 2, L-phenylalanine methyl ester 3, Lphenylalanine 4, and boric acid 5. Additionally, a non-boronated derivative, N,N-dimethylglycyI-Lphenylalanine methyl ester 6, was evaluated to determine the necessity of the boron atom for pharmacological activity ( Figure I ). The synthesis of boronated dipeptides was accomplished by using the coupling agent triphenylphosphine/carbon tetrachloride (Scheme I). The conditions under which this reaction was conducted were mild enough so that the yields were of acceptable levels compared to traditional condensation conditions, such as thionyl chloride, that result in the formation of chloroborane instead of the desired product [3] . The mechanism of PPh3/CCI4 condensation proceeds through the formation of a triphenyltrichloro-methylphosphonium chloride salt and subsequent formation of an acyloxyphosphonium salt. In the presence of an amino acid ester, the nitrogen reacts exclusively at the carbonyl carbon of the acyloxyphosphonium salt to form the dipeptide analog [3] .
Synthetic Methods: L-Phenylalanine methyl ester hydrochloride 3, L-phenylalanine 4, and boric acid 5, were purchased from Aldrich Chemical Company (Milwaukee, WI). Compound 1 was synthesized by the method of Sood et al. [1] . Compounds 2 and 6 were synthesized as follows: 
L-Phenylalanine methyl ester hydrochloride (2.09 g, 9.7 mmol) and dimethylglycine were suspended in 30 ml dry tetrahydrofuran (THF) with triethylamine (1.4 ml, 1.01 g, 10 mmol), dicyclohexylcarbodiimide (DCC, 2.24 ml, 2.06 g, 10 mmol) and hydroxybenzotriazole (HOBt, 1.35 g, 10 mmol). The reaction mixture was stirred at room temperature for 48 hours under nitrogen and the solvent was removed by rotary evaporation. The product was purified by silica gel column chromatography using two void volumes of hexane, two void volumes of hexane/ethanol (8:1), and then hexane:ethanol (5:1). In Vivo Hypolipidemic Activity: Compounds 1-3, and 6 demonstrated significant activity as hypolipidemic agents on both days 9 and 16, at 8 mg/kg/day, I.P., in CF male mice (Table II) . The compounds were similarly effective, reducing serum cholesterol levels in CF male mice 30-50%, on day 16. The most effective hypocholesterolemic agent was compound 1, which caused a 48% reduction in serum cholesterol levels on day 16. L-Phenylalanine methyl ester, 3, which reduced serum cholesterol levels 39%, on day 16, had similar efficacy as the other boron containing agents. L-phenylalanine, 4, and boric acid, 5, did not significantly reduce serum cholesterol levels over 16 days. Serum triglycerides were only significantly reduced by compounds 1, 3, and 6 on day 16 (Table II) . The L-phenylalanine methyl ester, 3, was approximately equally active as the parent compound 1. The other metabolites were not as active in reducing serum triglycerides at 8 mg/kg/day.
Winter's Test:
The ability to significantly reduce the carageenan induced inflammation in CF male mice footpads was demonstrated by compounds 1, 2 and 6 (Table III) . Compounds 3-5 did not appear to possess any activity. Compound 2 demonstrated the best inhibition of 40%. N,NdimethylglycyI-L-phenylalanine methyl ester, 6, was more active than the boronated parent compound, 1 with 32% inhibition compared to 23% inhibition at 8 mg/kg x 2 for the parent 1.
Writhing Assay:
All of the compounds tested demonstrated the ability to significantly block local pain (Table  III) . The most active compound from the derivatives of the boronated dipeptide N- [(trimethylamine-boryl) -carbonyl]-L-phenylalanine methyl ester was 6, which reduced mouse writhing reflex 52%, followed closely by 3, which provided a 50% reduction in writhing reflex. Both were significantly more active than the parent compound, 1 with 17% reduction at 8 mg/kg. All the compounds tested provided protection against LPS induced septic shock (Table III) . Compound 6, at 8 mg/kg/day, demonstrated the best protection against septic shock with 100% of the mice surviving. Compound 6 was significantly more active than the parent compound, 1 which demonstrated only 50 % protection at 8 mg/kg/day. After treatment with compounds 2-4 mouse survival was 83% after 48 hours, while treatment with compound 5 resulted in 67% mouse survival after 48 hours. All of the proposed metabolites of compound 1, compounds 3-6, were more effective than the parent compound. In the Winter's test compounds 2 and 6 (methyl ester derivatives) demonstrated slightly improved activity (32% and 40% respectively) over the parent 1 (23%) at 8 mg/kg. In the writhing / local pain assay compounds 3 and 6 demonstrated significantly improved activity (50-52% reduction) over the parent 1 (17% reduction), in the LPS endotoxic shock assay the parent 1 only resulted 50% protection from death. Compounds 2, 3, and 4 demonstrated improved protection with 83% and compound 6 afforded 100% protection suggesting that all of the metabolites with and without the methyl ester or boron were more effective than N-[(trimethylamineboryl)-carbonyl]-L-phenylalanine methyl ester 1. Thus it may be concluded that the metabolites of 1 were responsible for some of the observed pharmacological activity of compound 1. This response varied in mice with the type of pharmacological activity tested.
